PeptidePicker
Home/Peptides/Kyotorphin
NeuroprotectiveResearch

Kyotorphin

Also known as: L-Tyrosyl-L-Arginine · Tyr-Arg · KTP

An endogenous neuro-dipeptide with non-opioid analgesic properties and anti-amyloid activity, studied for pain management and Alzheimer's.

Dr. Sarah Mitchell

Reviewed by Dr. Sarah Mitchell, PharmD, BCPS

Lead Researcher · 12+ years in peptide therapeutics

Half-Life

~18 minutes

Typical Dose

Research dosing

Administration

Subcutaneous injection or intranasal

Mechanism of Action

Stimulates met-enkephalin release from neurons and inhibits amyloid-beta aggregation through direct peptide-peptide interaction.

Key Research Areas

painanalgesicnon-opioidAlzheimer's

Frequently Asked Questions

What is Kyotorphin?
An endogenous neuro-dipeptide with non-opioid analgesic properties and anti-amyloid activity, studied for pain management and Alzheimer's.
How does Kyotorphin work?
Stimulates met-enkephalin release from neurons and inhibits amyloid-beta aggregation through direct peptide-peptide interaction.
What is the recommended dosage for Kyotorphin?
The typical research dosage is Research dosing, administered via Subcutaneous injection or intranasal. Dosage protocols vary by study and should be determined by a qualified healthcare professional.
What is the half-life of Kyotorphin?
The half-life of Kyotorphin is approximately ~18 minutes. This affects dosing frequency and timing in research protocols.
Is Kyotorphin FDA approved?
Kyotorphin is currently classified as "Research" and is not FDA approved for general use. It is available for research purposes or through compounding pharmacies depending on your jurisdiction.

Research Disclaimer

The information provided about Kyotorphin is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare professional before starting any peptide protocol. Products discussed have not been evaluated by the FDA unless explicitly noted.

Related Peptides in Neuroprotective